ArticleChemMedChem2015
Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.
Article in ChemMedChem, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 110 citations in OpenAlex.
- A Triple-Stage Precision Carbon Dot Nanogel With Cascade Activation for Spatiotemporally Controlled Chemo-Photodynamic Therapy.Advanced healthcare materials · 2026Article
- Reframing Triazoloacridinone C-1305 as a G-Quadruplex Pharmacophore.The journal of physical chemistry. B · 2026Article
- Novel Cytotoxic Pt(IV) Compounds with Improved Safety Profiles.International journal of molecular sciences · 2026Article
- Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.Chemical reviews · 2025Review
- Hybrid Platinum(IV)-Naproxen Nanostructured Drugs Reprogram Melanoma Cells and Overpower Cisplatin.Nanomaterials (Basel, Switzerland) · 2025Article
- "Non-Classical" Platinum Complexes: A Concise Review.International journal of molecular sciences · 2025Review
- Novel Maleimide Linkers Based on a Piperazine Motif for Strongly Increased Aqueous Solubility.ACS omega · 2025Article
- Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs.Inorganic chemistry frontiers · 2023Article
- Platinum(IV) Derivatives of [Pt(1Journal of medicinal chemistry · 2023Article
- Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.International journal of molecular sciences · 2023Article
- Mesoporous Silica Nanoparticles Enhance the Anticancer Efficacy of Platinum(IV)-Phenolate Conjugates in Breast Cancer Cell Lines.Nanomaterials (Basel, Switzerland) · 2022Article
- Pro-Inflammatory Signalling PRRopels Cisplatin-Induced Toxicity.International journal of molecular sciences · 2022Review
- AbplatinJournal of nanobiotechnology · 2022Article
- Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity.Pharmaceutics · 2022Article
- Structure-Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands.Journal of medicinal chemistry · 2021Article
- Pt(IV) Prodrugs with NSAIDs as Axial Ligands.International journal of molecular sciences · 2021Review
- Albumin-encapsulated Nanoparticles of Naproxen Platinum(IV) Complexes with Inflammation Inhibitory Competence Displaying Effective Antitumor Activities in vitro and in vivo.International journal of nanomedicine · 2021Article
- Antiproliferative Activity of Pt(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and NaproxenInternational journal of molecular sciences · 2019Article
- Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance.Chemical science · 2018Article
- A Carrier-Free Nanostructure Based on Platinum(IV) Prodrug Enhances Cellular Uptake and Cytotoxicity.Molecular pharmaceutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Cyclooxygenase (COX) is an enzyme involved in tumorigenesis and is associated with tumor cell resistance against platinum-based antitumor drugs. Cisplatin analogues were conjugated with COX inhibitors (indomethacin, ibuprofen) to study the synergistic effects that were previously observed in combination treatments. The conjugates ensure concerted transport of both drugs into cells, and subsequent intracellular cleavage enables a dual-action mode. Whereas the platinum(II) complexes showed cytotoxicities similar to those of cisplatin, the platinum(IV) conjugates revealed highly increased cytotoxic activities and were able to completely overcome cisplatin-related resistance. Although some of the complexes are potent COX inhibitors, the conjugates appear to execute their cytotoxic action via COX-independent mechanisms. Instead, the increased lipophilicity and kinetic inertness of the conjugates seem to facilitate cellular accumulation of the platinum drugs and thus improve the efficacy of the antitumor agents. These conjugates are important tools for the elucidation of the direct influence of COX inhibitors on platinum-based anticancer drugs in tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.